Skip to main content
PLOS One logoLink to PLOS One
. 2021 Nov 8;16(11):e0245702. doi: 10.1371/journal.pone.0245702

Hydroxynonenal causes Langerhans cell degeneration in the pancreas of Japanese macaque monkeys

Piyakarn Boontem 1, Tetsumori Yamashima 1,2,*
Editor: David Chau3
PMCID: PMC8575276  PMID: 34748564

Abstract

Background

For their functions of insulin biosynthesis and glucose- and fatty acid- mediated insulin secretion, Langerhans β-cells require an intracellular milieu rich in oxygen. This requirement makes β-cells, with their constitutively low antioxidative defense, susceptible to the oxidative stress. Although much progress has been made in identifying its molecular basis in experimental systems, whether the oxidative stress due to excessive fatty acids plays a crucial role in the Langerhans cell degeneration in primates is still debated.

Methods

Focusing on Hsp70.1, which has dual functions as molecular chaperone and lysosomal stabilizer, the mechanism of lipotoxicity to Langerhans cells was studied using macaque monkeys after the consecutive injections of the lipid peroxidation product ‘hydroxynonenal’. Based on the ‘calpain-cathepsin hypothesis’ formulated in 1998, calpain activation, Hsp70.1 cleavage, and lysosomal integrity were studied by immunofluorescence histochemistry, electron microscopy, and Western blotting.

Results

Light microscopy showed more abundant vacuole formation in the hydroxynonenal-treated islet cells than the control cells. Electron microscopy showed that vacuolar changes, which were identified as enlarged rough ER, occurred mainly in β-cells followed by δ-cells. Intriguingly, both cell types showed a marked decrease in insulin and somatostatin granules. Furthermore, they exhibited marked increases in peroxisomes, autophagosomes/autolysosomes, lysosomal and peroxisomal membrane rupture/permeabilization, and mitochondrial degeneration. Disrupted peroxisomes were often localized in the close vicinity of degenerating mitochondria or autolysosomes. Immunofluorescence histochemical analysis showed an increased co-localization of activated μ-calpain and Hsp70.1 with the extralysosomal release of cathepsin B. Western blotting showed increases in μ-calpain activation, Hsp70.1 cleavage, and expression of the hydroxynonenal receptor GPR109A.

Conclusions

Taken together, these data implicate hydroxynonenal in both oxidation of Hsp70.1 and activation of μ-calpain. The calpain-mediated cleavage of the carbonylated Hsp70.1, may cause lysosomal membrane rupture/permeabilization. The low defense of primate Langerhans cells against hydroxynonenal and peroxisomally-generated hydrogen peroxide, was presumably overwhelmed to facilitate cell degeneration.

Introduction

The intracellular milieu of pancreatic β-cells is rich in oxygen, glucose and fatty acids for insulin biosynthesis and secretion. This makes β-cells, with their constitutively low enzymatic antioxidative defense equipment [1, 2], susceptible to oxidative stress during glucolipotoxicity. However, the mechanism of β-cell degeneration and death is not fully understood in type 2 diabetes until now. Hyperlipidemia (lipotoxicity) is accepted to be the greatest risk factor [3], because non-esterified fatty acids (NEFAs) are potent inducers of reactive oxygen species (ROS) through different mechanisms. β-cells exposed to oxidative, excessive or conjugated NEFAs develop cell degeneration/death [35]. The molecular mechanisms underlying the oxidative injury due to ROS, comprise of endoplasmic reticulum (ER) stress, mitochondrial dysfunction, impaired autophagy, lysosomal disintegrity, inflammation, and mixture of them [611].

These molecular events are grossly similar to the neurodegeneration of hypothalamic arcuate nucleus occurring after the intake of high-fat diets [12] or hippocampal CA1 sector exposed to the oxidative stress during reperfusion after transient ischemia [3, 13]. In 1998, Yamashima and his colleagues formulated the ‘calpain-cathepsin hypothesis’ as a mechanism of ischemic neuronal death [14, 15]. Thereafter, they suggested role of lysosomal rupture due to calpain-mediated cleavage of oxidized (carbonylated) heat-shock protein 70.1 (Hsp70.1; human type of Hsp70, also called Hsp72) as a mechanism of neuronal death [5, 1618]. However, previous researchers have not found so far any convincing molecular mechanism of a major contribution of ROS to the β-cell degeneration and death. Antioxidative defence mechanisms of β-cells would be overwhelmed by overproduction of ROS [19] such as superoxide radicals (O2•−), hydrogen peroxide (H2O2), and the most reactive and toxic hydroxyl radicals (OH•). Among these, OH• is responsible for the carbonylation of Hsp70.1 [16, 17], and its precursor H2O2 plays a central role in the deterioration of glucose tolerance in the development of type 2 diabetes [19]. The source of H2O2 in β-cells has been considered to be the electron transport chain in mitochondria. While this source is obviously important, peroxisomal generation of H2O2 is more crucial in β-cells [2023].

Lysosomes and peroxisomes, being contained in all eukaryote cells, are similar at the ultrastructural level but hold distinct enzymes for the completely different function. Lysosomes were discovered by the Belgian cytologist Christian de Duve in the 1950s [24]. They contain a wide variety of hydrolytic enzymes (acid hydrolases such as cathepsins B, L, etc.) which were produced in the rough ER, and are responsible for the digestion of macromolecules, old cell parts, and microorganisms. In oxygen-poor areas with an acidic environment (~pH4.5), lysosomes break down macromolecules such as damaged/aged/misfolded proteins, nucleic acids, and polysaccharides for the recycling. For this reason, an ATP-driven proton pump is located inside the double membrane which borders the lysosomes in order to pump H+ ions into their lumen. The double membrane surrounding the lysosome is vital to ensure cathepsins do not leak out into the cytoplasm and damage the cell from within. Recent data advocate for dual roles of Hsp70.1 not only as a molecular chaperone for damaged proteins but also as a guardian of lysosomal membrane integrity [25, 26]. Therefore, in case of Hsp70.1 dysfunction, not only failure of protein traffic and degradation (autophagy failure) but also lysosomal destabilization (cell degeneration and death) may occur.

Peroxisomes are single membrane-bounded organelles that are best-known for their involvement in both the cellular lipid metabolism and the cellular redox balance [2729]. Peroxisomes were first described by a Swedish doctoral student, J. Rhodin in 1954 [30], and were identified as a cell organelle by de Duve. He named them “peroxisomes”, replacing the formerly used morphological term “microbodies” [31]. De Duve and Baudhuin discovered that peroxisomes contain several oxidases involved in the production of H2O2 as well as catalase involved in the decomposition of H2O2 to oxygen and water [31, 32]. So, ‘peroxisomes’ owe their name to ‘hydrogen peroxide’ -generating and -scavenging activities. Peroxisomes are small spheroid organelles with a fine, granular matrix. Peroxisomes hold diverse oxidative enzymes that were produced at free ribosomes and require oxygen. To absorb nutrients that the cell has acquired, peroxisomes digest long-chain fatty acids and break them down into smaller molecules by β-oxidation. One of the byproducts of the β-oxidation is H2O2, so peroxisomes break H2O2, down into water (H2O) and O2. H2O2 itself is not very reactive, but Fe2+ or Fe3+ reacts with H2O2 to produce OH• in mitochondria. Accordingly, in both health and diseases, peroxisomes and mitochondria have a close relationship each other. Peroxisome generation, maintenance, and turnover are of great importance for the cellular homeostasis and survival. Peroxisomes are degraded by themselves or when fusing with lysosomes. The degradation takes just ~4 min, and half-life of peroxisomes is only 5 days.

The pathogenesis of β-cell dysfunction leading to insulin resistance and impaired insulin secretion seen in type 2 diabetes is incompletely understood. Previous animal and in vitro studies demonstrated that chronic levels of oxidative stress are among the earliest abnormalities in the natural history of type 2 diabetes, although the evidence is insufficient [6]. On the other hand, the evidence for inflammation in the etiology of type 2 diabetes is broad, however, the underlying mechanism is also not well understood. Increased oxidative stress and inflammation, combined together, may lead to the pancreatic β-cell failure [15]. Elevated levels of inflammatory markers, pro-oxidants and various markers of oxidative tissue damage were found in the diabetic patients, which indicates their involvement in the occurrence of insulin resistance and impaired insulin secretion. Peroxidation of polyunsaturated fatty acids is intensified in cells subjected to oxidative stress and inflammation, and it results in the generation of various bioactive compounds [610]. Reactive aldehyde, especially hydroxynonenal, is considered as the representative cytotoxic product of lipid peroxidation causing long-lasting biological consequences, in particular, by covalent modification of macromolecules. Hydroxynonenal is a major aldehyde which was produced during the OH•-mediated peroxidation of ω-6 polyunsaturated fatty acids. In 2009, Oikawa et al. (2009) [16] found by the proteomic analysis that Hsp70.1 can be a target of oxidation (carbonylation) by hydroxynonenal. Subsequently, Sahara and Yamashima (2010) [33] demonstrated by the in-vitro experiment that Hsp70.1 being carbonylated by hydroxynonenal is prone to activated μ-calpain-mediated cleavage. Calpain-mediated cleavage of carbonylated Hsp70.1 leads to the lysosomal membrane rupture/permeabilization with the resultant release of cathepsins and cell death.

It is well-known that insulin resistance and impaired insulin signalling may be a contributory factor to the progression of type 2 diabetes. Although reduced release of insulin from β-cells is fundamental for both, the molecular mechanism of the Langerhans cell dysfunction caused by chronic inflammation and oxidative stress remains grossly unknown. Much progress has been made in identifying the molecular basis of lipotoxicity in the experimental systems, however whether or not this phenomenon actually plays an important role for the Langerhans cell degeneration remains debated especially in the primates [10]. To overcome this controversy, the authors thought that the experimental paradigm using non-human primates is indispensable. In the preliminary study, we confirmed that the intravenous injections of the synthetic hydroxynonenal induced cell death of diverse brain neurons and hepatocytes of the Japanese macaque monkeys [18]. To elucidate the etiology of the Langerhans cell degeneration/death causing impaired insulin secretion, we made an appropriate monkey model for an increased blood concentration of hydroxynonenal to analyse its toxic effects upon the Langerhans islet. We focused on the pancreas of monkeys to elucidate the molecular cascade processing in the primate organ. The pancreas of monkeys is large enough to supply sufficient amount of tissues necessary for the simultaneous analyses of immunofluorescence histochemistry, light and electron microscopy, and Western blotting in the given animal. Here, we report that hydroxynonenal can induce lysosomal membrane rupture/permeabilization by activated calpain-mediated cleavage of the carbonylated Hsp70.1 for the occurrence of Langerhans cell degeneration/death.

Materials and methods

Animals

After the referee of animal experimentation about the ethical or animal welfare, four young (4~5 years: compatible with teenagers in humans) female Japanese macaque monkeys (Macaca fuscata) were supplied by National Bio-Resource Project (NBRP) “Japanese monkey” (National Institute for Physiological Sciences, Okazaki, Japan). After arrival, the monkeys were reared in the wide cage with autofeeding and autodrainage machines as well as appropriate toys to play at least for 1 year to facilitate acclimation. The room temperature was kept 22~24°C with the humidity of 40~50%. They were fed by 350 kCal/Kg body weight of non-purified solid monkey foods per day containing vitamines. and apples, pumpkins or sweet potatoes were given twice every week. In the morning and afternoon, an animal care staff and the first author monitored the health and well-being of the animals to check the consumption of foods, pupilar reflex to the light, and conditions of standing and jumping.

At 5~6 years of age, monkeys with body weight 5~7 Kg were randomly divided into two different groups of the sham-operated control (n = 1) and those undergoing hyroxynonenal injections (n = 3). In 3 monkeys, under the intramuscular anesthesia using 2 mg/Kg of kethamine hydrochrolide, intravenous injections of 5 mg/week of synthetic hydroxynonenal (Cayman Chemical, Michigan, USA) were done for 24 weeks. Such doses and serial injections were designed to temporarily mimic blood concentrations of hydroxynonenal in humans around 60’s [34]. Behavioural changes such as reduced exploration, standing, and jumping as well as decreases of appetite and body weight were carefully monitored to implement humane endpoints. However, all the monkeys were fine until the end of final 24th hydroxynonenal injections.

Tissue collection

Six months after the initial injection and within a couple of weeks after the final injection, the monkeys were immobilized by the intramuscular injection of 10 mg/Kg BW ketamine hydrochloride followed by the intravenous injection of 50 mg/Kg BW sodium pentobarbital. In addition, to ameliorate animal suffering, the monkey was deeply anesthetized with 1.5% halothane plus 60% nitrous oxide. After the perfusion of 500 mL saline through the left ventricle, the pancreas was removed without suffering any pain. Half of the tissue was fixed in either i) 4% paraformaldehyde for light microscopy, or ii) 2.5% glutaraldehyde for electron microscopy. The remaining half was stocked in the -80°C deep freezer for the Western blotting analysis.

Histological and immunofluorescence histochemical analyses

The pancreas tissues after fixation with 4% paraformaldehyde for 2 weeks were embedded in paraffin, and 5μm sections were stained by hematoxylin-eosin. For the immunofluorescence histochemistry, the cryoprotected pancreas tissues embedded in the OCT medium (Sakura Finetek, Japan) were cut by cryotome (Tissue-Tek® Polar®, Sakura, Japan), and 5μm sections were immersed with heated 0.01% Citrate retrieval buffer to induce epitope retrieval. Non-specific staining was blocked with 1% bovine serum albumin (Nacalai tesque, Japan), and were incubated overnight at 4°C with the primary antibodies at the dilution of 1:100. We used mouse monoclonal anti-human Hsp70 (BD Bioscience, USA), rabbit anti-human activated μ-calpain (order made by PEPTIDE Institute, Japan), rabbit anti-human cathepsin B (Cell Signaling, USA), and mouse monoclonal anti-Lamp2 (Abcam, USA) antibodies. After washings, the sections were incubated for 30 min with secondary antibodies; Alexa FluorTM 594 goat anti-mouse IgG [H+L] (Invitrogen, USA), or Alexa FluorTM 488 goat anti-rabbit IgG (Invitrogen, USA) at the dilution of 1:500. To block autofluorescent staining, Autofluorescence Quenching Kit (Vector Laboratories, USA) was utilized. The immunoreactivity was observed with the laser confocal microscope (LSM5 PASCAL, Software ZEN 2009, Carls Zeiss, Germany).

Ultrastructural analyses

For the electron microscopic analysis, small specimens of the pancreas tissue were fixed with 2.5% glutaraldehyde for 2h and 1% OsO4 for 1h. Subsequently, they were dehydrated with graded acetone, embedded in resin (Quetol 812, Nisshin EM Co. Tokyo), and thin sections were made. After trimming with 0.5% toluidine blue-stained sections, the ultrathin (70nm) sections of appropriate portions were stained with uranyl acetate (15 min) and lead citrate (3 min), and were observed by the electron microscope (JEM-1400 Plus, JEOL Ltd., Tokyo).

Western blotting

Total protein extraction was done, using protease inhibitor cocktail (Sigma-Aldrich, USA) and PhosSTOP phosphatase inhibitor cocktails tablets (Roche, Germany). After centrifugation at 12,000 rpm for 10 min, the supernatant proteins were determined by Bradford Assay (Thermo Fisher, USA). Twenty μg proteins were separated by SDS-PAGE in SuperSep (TM) Ace 5–20% gel (Wako, Japan) at 40 mA for 1h. The total proteins were transferred to PVDF membrane (Millipore, USA). Transferred protein quantities were detected with Ponseau S solution (Sigma-Aldrich, USA). Transferred proteins were blocked with 1% BSA (KPL DetectorTM Block, USA) for 1h. The blots were incubated with mouse monoclonal anti-human Hsp70 antibody (BD Bioscience, USA) at the dilution of 1:4,000, rabbit anti-human activated μ-calpain antibody (PEPTIDE Institute, Japan) at 1:250 overnight, or rabbit anti-human GPR109A (also called hydroxycarboxylic acid receptor 2) antibody (Abcam, USA) at 1:500. β-actin was utilized as an internal control at a dilution of 10,000 (Sigma-Aldrich, USA). The immunoblots were subsequently incubated for 1h with secondary antibodies at 1:10,000 dilution of anti-mouse (Santa Cruz, USA) or anti-rabbit IgG (Sigma, USA). An enhanced chemiluminescence (ECL) HRP substrate detection kit (Millipore, USA) was used to visualize the reactive protein bands with ImageQuant LAS 4000 mini (GE Life Science, USA).

Ethics

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Kanazawa University Graduate School of Medical Sciences (Protocol Number: AP-153613).

Results

By light microscopy, the Langerhans islets after the hydroxynonenal injections showed formation of many vacuoles, compared to the control, which were often filled with eosinophilic substance or looked almost empty (Fig 1). Nuclear chromatin of Langerhans cells was generally more dense than the control, which was consistent with the electron microscopic finding (Fig 2). A small number of nuclei showed dissolution of chromatin or punctuate condensation (Fig 1, dot circle). However, neither apoptotic bodies nor membrane blebbings were observed in the Langerhans islet cells after the hydroxynonenal injections.

Fig 1.

Fig 1

Light micrograph of the monkey pancreas. The Langerhans islet after the hydroxynonenal injections (HNE) shows many vacuole formation (circles), compared to the sham-operated control (Cont). Nuclear chromatin is generally more dense after the hydroxynonenal injections, compared to the control. A small number of nucleus shows diffuse dissolution or punctuate condensation (dot circle). However, neither apoptotic bodies nor membrane blebbings were seen. Acinar cells are distributed in the surrounding area. Hematoxylin-eosin staining.

Fig 2. Electron micrograph of the Langerhans islet of the monkey before and after the hydroxynonenal injections.

Fig 2

The Langerhans islet cells are situated surrounding a capillary (Cap), and each cell is characterized by peculiar secretory granules. Insulin secretory granules of the β-cell (β) are the largest with a clear halo. Glucagon secretory granules of the α-cell (α) lack a clear halo, being a little bit smaller but more electron-dense than insulin granules. Somatostatin-containing granules of the δ-cell (δ) are also electron-dense like glucagon granules, showing a sparse distribution. PP-cells (PP) contain spherical or elliptical small granules, which are very heterogeneous in size. The greatest changes after the hydroxynonenal injections are a remarkable decrease of insulin and somatostatin granules as well as an increase of autophagosomes and autolysosomes. In the control β-cell (Cont), insulin granules were distributed throughout the cytoplasm. In contrast, in the β-cell after the hydroxynonenal injections (HNE), the distribution of insulin granules was restricted in the cytoplasm toward the capillary. Instead, especially β-cell showed formation of many autolysosomes (circles), compared to the control (Cont). Further, both β-cell and δ-cell showed vacuole formations (stars) and more electron-dense nuclear chromatin. N; nucleus.

The Langerhans islets are known to be basically composed of α-, β-, δ- cells and pancreatic polypeptide cells (PP-cells). As described previously in humans [35, 36], electron microscope was useful for differentiating 4 types of cells in the Langerhans islets of monkeys. In β-cells (β), insulin secretory granules had an electron-opaque core of 300–400 nm with a clear halo (Figs 25), while in α-cells (α), glucagon secretory granules were electron-dense without a clear halo. Compared to the insulin secretory granules, the glucagon granules were more electron-dense with a smaller diameter (200–300 nm) (Fig 2). δ-cells (δ) exhibit neuron- or trumpet- like morphology with cytoplasmic processes extending from the islet capillaries (Fig 2). Somatostatin-containing granules were also electron-dense, showing a similar size with glucagon granules, but showed a sparse distribution (Fig 6A and 6B). PP-cells (PP) contained spherical smaller granules, which were heterogeneous in size (Fig 2).

Fig 5. Electron micrograph of the β-cell in the monkey after the hydroxynonenal injections.

Fig 5

β-cell shows enlargement of rough ER (ER), as seen in Fig 2. Proliferation of peroxisomes (P) is obvious, and they are intermingled with degenerating mitochondria and insulin granules in the cytoplasm toward the capillary lumen, as seen in Fig 2. Some peroxisomes with membrane disruptions (arrows) are fusing with degenerating mitochondria (m, circles) or autolysosomes presumably containing mitochondrial debris (dot circles). G: insulin granule.

Fig 6.

Fig 6

a) Electron micrograph of the δ-cell in the monkey after the hydroxynonenal injections. δ-cell shows fusion of an autolysosome (Al) with a peroxisome (P) exhibiting membrane disruption. G: somatostatin granule without a halo, Ly: lysosome. b) Electron micrograph of the δ-cell in the monkey after the hydroxynonenal injections. δ-cell shows peroxisomal proliferation (P) around the autolysosomes (Al). The latter are presumably in the process of fusing with peroxisomes (P). Some peroxisomes show membrane disruption (arrows). ER: rough ER.

By the electron microscopic observation, the most remarkable change in the Langerhans cells after the hydroxynonenal injections was a remarkable decrease of insulin and somatostatin granules (Fig 2, HNE), compared to the control (Fig 2, Cont). The decrease was evident, when compared with human β- and δ- cells whose cytoplasm was filled with insulin and somatostatin granules [36]. In the control β-cells of monkeys also, insulin granules were distributed throughout the cytoplasm (Fig 2, Cont), whereas in the Langerhans islets after the hydroxynonenal injections, they were clustered in the cytoplasm toward the capillary lumen (Fig 2, HNE). Among α-, β-, δ- and PP- cells of the islets after the hydroxynonenal injections, β- and δ- cells showed lots of vacuole formations which were revealed to be enlarged rough ER with a marked decrease of ribosomes (Fig 2 stars, Fig 5), indicating ER dysfunction. Further, β- and δ- cells after the hydroxynonenal injections were ultrastructurally characterized by peroxisomal proliferation (Figs 5 and 6B), and increments of autophagosomes or autolysosomes (Figs 25, 6A and 6B), which were extremely rare in the control tissue (Fig 2, Cont).

By the electron microscopic observation of the pancreas, lysosomes were relatively electron-dense organelles homogenously filled with microvesicular granules, while peroxisomes contained a less-dense matrix with fine granules. So, the limiting membrane was more clearly visible in peroxisomes than lysosomes. In the β-cells after the hydroxynonenal injections, lysosomes were often distributed around the autophagosomes or autolysosomes throughout the cytoplasm (Figs 2 and 3), while peroxisomes were distributed around insulin granules, being intermingled with degenerating mitochondria in the cytoplasm toward the capillary lumen (Fig 5). At the high magnification, degenerating β-cells (Fig 3) and δ-cells (Fig 6A) contained an autophagosome which was in the process of fusing with the lysosome showing membrane permeabilization. Autophagosome or autolysosome was observed to fuse also with peroxisome which was surrounded by the disrupted membrane (Figs 4 and 6B). Peroxisomes with membrane disruption were abundant around insulin and somatostatin granules in the cytoplasm toward the capillary lumen (Figs 4 and 6A). Some peroxisomes were seen to fuse with degenerating mitochondria (Fig 5, circles) or in the close vicinity of autolysosomes (Fig 5, dot circles). As β-cells and δ-cells showed a similar change, β-cells generally showed a stronger degeneration than δ-cells.

Fig 3. Electron micrograph of the β-cell in the monkey after the hydroxynonenal injections.

Fig 3

β-cell shows fusion of an autophagosome (AP) with a lysosome (Ly) exhibiting evidence of membrane permeabilization (arrows). This autophagosome is devoid of double membrane, whereas another one (Ap) presumably containing degenerated mitochondria, has distinct double membrane. G: insulin granule.

Fig 4. Electron micrograph of the β-cell in the monkey after the hydroxynonenal injections.

Fig 4

β-cell shows fusion of an autolysosome (Al) with a peroxisome (P) exhibiting membrane disruption (arrows). The autolysosome (Al) contains mitochondria-derived debris (asterisk). The neighbouring lysosome (Ly) shows membrane permeabilization. G: insulin granule, Ap: autophagosome, m: degenerating mitochondria.

Immunofluorescence histochemical analysis showed a remarkable increase of Hsp70.1 colocalization with activated μ-calpain in the Langerhans islets after the hydroxynonenal injections (Fig 7A, HNE, merged color), comparted to the control (Fig 7A, Cont). In the control, the cathepsin B immunoreactivity was seen as tiny granules which were compatible with the size of intact lysosomes (Fig 7B, Cont). However, after the hydroxynonenal injections, cathepsin B immunoreactivity was seen as coarse granules with a diffuse, thin distribution throughout the cytoplasm (Fig 7B, HNE). In the core of cathepsin B immunoreactivity, lamp-2 immunoreactivity was colocalized with a merged color (data not shown here), which showed extralysosomal release of cathepsin enzymes by the lysosomal membrane rupture/permeabilization.

Fig 7. Calpain activation, Hsp70.1 cleavage, and cathepsin B leakage.

Fig 7

a) Immunofluorescence histochemical staining of Hsp70.1 (red) and activated μ-calpain (green). Activated μ-calpain immunoreactivity is negligible without hydroxynonenal injections (Cont), whereas μ-calpain activation occurs with hydroxynonenal injections (HNE), being consistent with the Western blotting data (c, activated μ-calpain). After hydroxynonenal injections, activated μ-calpain immunoreactivity (green) is colocalized with Hsp70.1 immunoreactivity (red), showing a merged color of yellow (HNE, yellow). The distribution pattern of granular merged colors is compatible with that of autolysosomes as seen in Fig 2. b) Immunofluorescence histochemical staining of cathepsin B (green). Cathepsin B is stained as tiny granules in the control Langerhans islet (Cont), whereas stained as coarse granules with the perigranular immunoreactivity after hydroxynonenal injections (HNE), which indicates lysosomal membrane rupture/permeabilization. The nuclei show negligible cathepsin B immunoreactivity. Cathepsin B immunoreactivity was colocalized with that of Lamp2 (data not shown here). c, d) Western blotting analyses of activated μ-calpain (c, 76 kDa), GPR109A (c, 41.8 kDa), and Hsp70.1 (d, 70 kDa). Compared to the control (c, Cont), μ-calpain is activated after hydroxynonenal injections (c, HNE). In response to the cell stress due to hydroxynonenal injections (d, HNE), not only Hsp70.1 main bands (d, rectangle) but also cleaved Hsp70.1 bands of 30 kDa (d, dot rectangle) are increased, compared to the control (d, Cont). GPR109A is expressed in the pancreas tissue, although showing no change after hydroxynonenal injections (c, GPR109A).

Western blotting showed an increase of 76 kDa band intensities of activated μ-calpain after the hydroxynonenal injections, compared to the control (Fig 7C, rectangle). In response to such stress, the main bands of Hsp70.1 are increased remarkably, compared to the control (Fig 7D, rectangle). In addition, calpain-mediated Hsp70.1 cleavage [33], as shown in 30 kDa bands (Fig 7D, dot rectangle), are increased in the monkeys after hydroxynonenal injections. Repeated Western blotting showed the same results, although the statistical significance was not available because of the restricted number of experimental animals. GPR109A was expressed equally in the control and hydroxynonenal-injected tissues (Fig 7C).

Discussion

In type 2 diabetes, β-cell degeneration and death contribute to the loss of its functional mass [8, 37, 38]. However, surprisingly, the underlying molecular mechanism remains grossly unknown until now, although β-cell lipotoxicity has been subject to intensive research for the past two decades [3941]. As most studies showing deleterious effects of elevated NFFAs on β-cell function were conducted in vitro, the contribution of elevated NEFAs to β-cell dysfunction in human patients with type 2 diabetes still remains controversial [41]. Not only quantity but also quality (i.e. extent and type of oxidization) of NEFAs may impact β-cell function [10].

In the pancreas, two types of fatty acid receptor emerge as a cause of abnormal Ca2+ mobilization in response to excessive and/or oxidized NEFAs; one is G protein-coupled receptor 40 (GPR40) while another is GPR109A. GPR40 is a receptor for diverse NEFAs, being expressed abundantly in the β-cells [42, 43]. Steneberg et al. (2005) [44] proposed that GPR40 is indirectly responsible for hyperinsulinemia-induced insulin resistance, whereas other researchers reported that NEFA-induced hyperinsulinemia represents a mechanism by which β-cells attempt to compensate for the insulin resistance because this ability is compromised by GPR40 deletion [45, 46]. Accordingly, implication of GPR40 for the development of β-cell lipotoxicity in response to excessive NEFAs still remains debated [5]. Albeit GPR40 is abundantly expressed in the primate pancreas [42, 43] including the present macaque monkeys (data not shown), for this reason we focused here on the expression of a metabolic sensor GPR109A in the monkey pancreas. Since in response to hydroxynonenal GPR109A was demonstrated to induce excessive Ca2+ mobilization and the subsequent cell death in the retinal pigmented and colon epithelial cells [47], we speculated that the same may occur in β-cells where GPR109A is expressed.

Previous reports suggest that oxidative stress during metabolizing excessive NEFAs mediates lipotoxicity. As NEFAs are metabolized not only through mitochondrial β-oxidation but also through peroxisomal β-oxidation, the subcellular sites of ROS formation are mitochondria and peroxisomes [27, 28, 48]. In contrast to the mitochondrial β-oxidation, however, the acyl-CoA oxidases generate more H2O2 in the peroxisomes [49]. Now, almost 50 years after their discovery, it is well known that peroxisomes can function as a main source of ROS [50]. As β-cells almost completely lack catalase, they are thought to be exceptionally vulnerable to abundant H2O2 which was presumably generated in the increased number of peroxisomes (Fig 5).

It is well known that peroxisomes are highly plastic, dynamic organelles that rapidly modulate their size, number, and enzyme content in response to changing environmental conditions [51, 52]. The present study showed a remarkable peroxisomal proliferation in β-cells after the hydroxynonenal injections (Figs 5 and 6B). Inactivation of H2O2 by catalase seems to be a step of critical importance for the removal of ROS in β-cells. However, since β-cells almost completely lack the H2O2-detoxifying enzyme, oxidoreductase catalase [1, 2], they are exceptionally vulnerable to H2O2 that was generated in peroxisomes. If H2O2 is not quickly converted into water and oxygen by catalase, it can react in an iron-catalysed reaction with O2•− yielding the highly reactive OH•. It is the most reactive oxygen radical known, reacting instantaneously with molecules in its immediate vicinity, which explains its great destructive power. This conceivably causes β-cell dysfunction, degeneration, and ultimately cell death, because of its low antioxidative defense status [23]. Since mitochondria also lack catalase and, in β-cells, mitochondria contain an extremely low glutathione peroxidase activity, any excessive oxidative stress is detrimental for the β-cell mitochondria due to the limited antioxidative defence capacity [19]. The capacity for inactivation of H2O2 is sufficient under normal circumstances, however, during the consecutive oxidative stress like the present experimental paradigm (5mg/W x 24 week injections of hydroxynonenal), a constant level of H2O2 might have been continuously generated within both mitochondria and peroxisomes. So, low anti-oxidative defence of β-cells can be easily overwhelmed in pathological situations of sustained OH• production. The close spatial relation of mitochondria with crista disruption and peroxisome with membrane disruption (Fig 5), indicates a strong impact of hydroxynonenal upon β-cells.

Peroxisomal degradation occurs through at least three different mechanisms: macropexophagy, micropexophagy, and 15-lipoxygenase-mediated autolysis [53, 54]. A lipid-peroxidizing enzyme, 15-lipoxygenase can generate hydroxynonenal from ω-6 polyunsaturated fatty acids of biomembranes. As 15-lipoxygenase is distributed in peroxisomes at the highest concentration [55], it initiates organelle degradation by pore formation in the limiting membranes [56, 57]. van Leyen et al. (1998) [58] demonstrated that 15-lipoxygenase can bind to organelle membranes and induce the leakage of its contents. Yokota et al. (2001) [55] also showed induction of the peroxisomal membrane disruption and the resultant catalase leakage by 15-lipoxygenase in the rat liver. Interestingly, such 15-lipoxygenase-induced peroxisomal membrane disruptions were very similar at the ultrastructural level to those observed in the monkey Langerhans cells after the hydroxynonenal injections (Figs 5 and 6B). Hydroxynonenal is generated as a consequence of H2O2-mediated lipid peroxidation of biomembranes composing of ω-6 polyunsaturated fatty acids such as linoleic and arachidonic acid [11, 59, 60]. Therefore, it is reasonable to speculate that exogenous hydroxynonenal is a causative substance and also a trigger, which induce consecutive peroxisomal HO• production with the resultant intrinsic hydroxynonenal generation in the monkey pancreas (Fig 8). Hydroxynonenal has been increasingly recognized as a particularly important mediator of dysfunction and degeneration of pancreatic β cells in type 2 diabetes and alcohol-induced pancreatic damage [19, 61]. There is ample evidence that hydroxynonenal causes cell dysfunction and death in diverse disorders including Alzheimer’s disease [62, 63], cardiovascular disease, stroke, arthritis and asthma [6467]. By activating GPR109A, hydroxynonenal can be a trigger for the excessive Ca2+ mobilization and subsequent calpain activation [68]. So, it is reasonable that the Langerhans cells with GPR109A expression showed an increased activation of μ-calpain in response to the exogenous hydroxynonenal.

Fig 8. The molecular cascade explaining degeneration of β- and δ- cells in the Langerhans islet of the monkey after hydroxynonenal injections.

Fig 8

Peroxisomes play a crucial role for the sustained H2O2 production, while calpain-mediated cleavage of carbonylated Hsp70.1 causes lysosomal membrane rupture/permeabilization. In both cascades, hydroxynonenal plays a central role for the β- and δ- cell degeneration.

Concerning the molecular mechanism of ischemic neuronal death, Yamashima et al. formulated the ‘calpain-cathepsin hypothesis’ in 1998 [14]. Thereafter, concerning the mechanism of Alzheimer’s neuronal death, they suggested that Hsp70.1 with dual functions of molecular chaperone and lysosomal stabilizer becomes vulnerable to the cleavage by activated μ-calpain, which is facilitated after Hsp70.1 oxidation (carbonylation) by hydroxynonenal [33, 6971]. Elevated hydroxynonenal was recently reported to be responsible for hyperglycemia and correlated with HbA1c in both experimental animals and humans [72], although the precise role of hydroxynonenal in type 2 diabetes is not well understood until now. Due to the hydroxynonenal-induced carbonylation with the subsequent calpain-mediated cleavage of carbonylated Hsp70.1, functional Hsp70.1 decreases steadily. This results in both accumulation of autophagosomes and permeabilization/rupture of the lysosomal membrane (Fig 8). It is likely that autophagy deficiency and lysosomal failure are occurring simultaneously. By inducing Hsp70.1 disorder, hydroxynonenal conceivably plays sinister roles in the occurrence of degeneration/death of Langerhans cells, leading to type 2 diabetes.

Applying the data of the present monkey experimental paradigm to consider human diseases, both the dietary ω-6 fatty acid- (exogenous; from cooking oils, deep-fried foods, etc.) and the biomembrane phospholipid- (intrinsic; from the circumstance containing electromagnetic wave, air pollution, etc.) peroxidation product hydroxynonenal, when combined, conceivably plays crucial roles for the lysosomal cell death not only in the pancreas but also in the brain. The authors speculate that not only type 2 diabetes but also Alzheimer’s disease might occur in response to the exogenous and intrinsic hydroxynonenal by the long-standing lysosomal cell death in the corresponding organ [11].

Conclusions

During the last four decades, hydroxynonenal, a major α, β-unsaturated aldehyde product of ω-6 fatty acid oxidation, has been shown to be involved in a great number of pathologies such as metabolic diseases, neurodegenerative diseases, and cancers. The present study indicated that a major pathophysiological mechanism behind the development of Langerhans cell degeneration/death is oxidative stress mediated by hydroxynonenal. By carbonylating a lysosomal stabilizer, Hsp70.1, hydroxynonenal contributes to the occurrence of lysosomal membrane rupture/permeabilization in the Langerhans cells, which lead to their degeneration/death. Calpain activation by hydroxynonenal may contribute to cleavage of the oxidized (carbonylated) Hsp70.1. In case of the above diseases, chronic ischemia and/or inflammation may also facilitate calpain activation. The low defense against exogenous hydroxynonenal and peroxisomally-generated hydrogen peroxide, was presumably overwhelmed in the Langerhans islets. The authors speculate from the present monkey data that ‘hydroxynonenal’ might be a real culprit behind type 2 diabetes in humans. Future studies focusing on the earlier phase of hydroxynonenal toxification in vivo, are needed to elucidate the molecular mechanism of the Langerhans cell pathology for the development of type 2 diabetes.

Supporting information

S1 Data

(PDF)

Acknowledgments

The authors are deeply indebted to Mr. Jun Uchimoto for the daily care of monkeys and autopsy assistance, Mrs. Katsumi Hara and Mrs. Masayo Baba for the tissue preparation, and Mrs. Rie Nishioka and Mrs. Mai Nakayama for the secretory work.

List of abbreviations

ER

endoplasmic reticulum

Hsp70.1

heat-shock protein 70.1

H2O2

hydrogen peroxide

OH•

hydroxyl radicals

NEFAs

nonesterified fatty acids

ROS

reactive oxygen species

O2•−

superoxide radicals

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by a grant from Kiban-Kenkyu (B) (19H04029) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med. 1996;20(3):463–6. doi: 10.1016/0891-5849(96)02051-5 [DOI] [PubMed] [Google Scholar]
  • 2.Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes. 1997. Nov;46(11):1733–42. doi: 10.2337/diab.46.11.1733 [DOI] [PubMed] [Google Scholar]
  • 3.Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. 1999. Jul;159(13):1450–6. doi: 10.1001/archinte.159.13.1450 [DOI] [PubMed] [Google Scholar]
  • 4.Diakogiannaki E, Dhayal S, Childs CE, Calder PC, Welters HJ, Morgan NG. Mechanisms involved in the cytotoxic and cytoprotective actions of saturated versus monounsaturated long-chain fatty acids in pancreatic beta-cells. J Endocrinol. 2007. Aug;194(2):283–91. doi: 10.1677/JOE-07-0082 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Yamashima T. Dual effects of the non-esterified fatty acid receptor “GPR40” for human health. Prog Lipid Res. 2015. Apr;58:40–50. doi: 10.1016/j.plipres.2015.01.002 [DOI] [PubMed] [Google Scholar]
  • 6.Odegaard AO, Jacobs DR Jr, Sanchez OA, Goff DC, Reiner AP, Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 2016. Mar; 15:51. doi: 10.1186/s12933-016-0369-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes. 2005. Dec;54 Suppl 2:S108–13. doi: 10.2337/diabetes.54.suppl_2.s108 [DOI] [PubMed] [Google Scholar]
  • 8.Laybutt DR, Preston AM, Akerfeldt MC, Kench JG, Busch AK, Biankin A V, et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia. 2007. Apr;50(4):752–63. doi: 10.1007/s00125-006-0590-z [DOI] [PubMed] [Google Scholar]
  • 9.Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest. 2008. Oct;118(10):3378–89. doi: 10.1172/JCI34587 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lytrivi M, Castell A-L, Poitout V, Cnop M. Recent insights into mechanisms of β-cell lipo- and glucolipotoxicity in type 2 diabetes. J Mol Biol. 2020. Mar;432(5):1514–34. doi: 10.1016/j.jmb.2019.09.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yamashima T, Ota T, Mizukoshi E, Nakamura H, Yamamoto Y, Kikuchi M, et al. Intake of ω-6 polyunsaturated fatty acid-rich vegetable oils and risk of lifestyle diseases. Adv Nutr. 2020. Nov;11(6):1489–509. doi: 10.1093/advances/nmaa072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Thaler JP, Yi C-X, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012. Jan;122(1):153–62. doi: 10.1172/JCI59660 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yamashima T, Saido TC, Takita M, Miyazawa A, Yamano J, Miyakawa A, et al. Transient brain ischaemia provokes Ca2+, PIP2 and calpain responses prior to delayed neuronal death in monkeys. Eur J Neurosci. 1996. Sep;8(9):1932–44. doi: 10.1111/j.1460-9568.1996.tb01337.x [DOI] [PubMed] [Google Scholar]
  • 14.Yamashima T, Kohda Y, Tsuchiya K, Ueno T, Yamashita J, Yoshioka T, et al. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on “calpain-cathepsin hypothesis”. Eur J Neurosci. 1998. May;10(5):1723–33. doi: 10.1046/j.1460-9568.1998.00184.x [DOI] [PubMed] [Google Scholar]
  • 15.Yamashima T. Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates. Prog Neurobiol. 2000. Oct;62:273–95. doi: 10.1016/s0301-0082(00)00006-x [DOI] [PubMed] [Google Scholar]
  • 16.Oikawa S, Yamada T, Minohata T, Kobayashi H, Furukawa A, Tada-Oikawa S, et al. Proteomic identification of carbonylated proteins in the monkey hippocampus after ischemia-reperfusion. Free Radic Biol Med. 2009. Jun;46(11):1472–7. doi: 10.1016/j.freeradbiomed.2009.02.029 [DOI] [PubMed] [Google Scholar]
  • 17.Yamashima T, Oikawa S. The role of lysosomal rupture in neuronal death. Prog Neurobiol. 2009. Dec;89(4):343–58. doi: 10.1016/j.pneurobio.2009.09.003 [DOI] [PubMed] [Google Scholar]
  • 18.Yamashima T, Boontem P, Shimizu H, Ota T, Kikuchi M, Yamashita T, et al. Vegetable oil-derived hydroxynonenal causes diverse cell death possibly leading to Alzheimers and related lifestyle diseases. J Alzheimers Dis Parkinsonism. 2020. Jan;10(1):483. https://www.omicsonline.org/open-access/vegetable-oilderived-hydroxynonenal-causes-diverse-cell-death-possibly-leading-to-alzheimers-and-related-lifestyle-disea.pdf [Google Scholar]
  • 19.Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans. 2008. Jun;36(Pt 3):343–7. doi: 10.1042/BST0360343 [DOI] [PubMed] [Google Scholar]
  • 20.Newsholme P, Haber EP, Hirabara SM, Rebelato ELO, Procopio J, Morgan D, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007. Aug;583(Pt 1):9–24. doi: 10.1113/jphysiol.2007.135871 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Schönfeld P, Wojtczak L. Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic Biol Med. 2008. Aug;45(3):231–41. doi: 10.1016/j.freeradbiomed.2008.04.029 [DOI] [PubMed] [Google Scholar]
  • 22.Elsner M, Gehrmann W, Lenzen S. Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells. Diabetes. 2011. Jan;60(1):200–8. doi: 10.2337/db09-1401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic β-cells. Diabetes Obes Metab. 2010. Oct;12 Suppl 2:149–58. doi: 10.1111/j.1463-1326.2010.01265.x [DOI] [PubMed] [Google Scholar]
  • 24.De Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J. 1955. Aug;60(4):604–17. doi: 10.1042/bj0600604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kirkegaard T, Roth AG, Petersen NHT, Mahalka AK, Olsen OD, Moilanen I, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature. 2010. Jan;463(7280):549–53. doi: 10.1038/nature08710 [DOI] [PubMed] [Google Scholar]
  • 26.Petersen NHT, Kirkegaard T, Olsen OD, Jäättelä M. Connecting Hsp70, sphingolipid metabolism and lysosomal stability. Cell Cycle. 2010. Jun;9(12):2305–9. doi: 10.4161/cc.9.12.12052 [DOI] [PubMed] [Google Scholar]
  • 27.Wanders RJA, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem. 2006. Jul;75:295–332. doi: 10.1146/annurev.biochem.74.082803.133329 [DOI] [PubMed] [Google Scholar]
  • 28.Van Veldhoven PP. Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. J Lipid Res. 2010. Oct;51(10):2863–95. doi: 10.1194/jlr.R005959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Fransen M, Nordgren M, Wang B, Apanasets O. Role of peroxisomes in ROS/RNS-metabolism: Implications for human disease. Biochim Biophys Acta—Mol Basis Dis. 2012. Sep;1822(9):1363–73. doi: 10.1016/j.bbadis.2011.12.001 [DOI] [PubMed] [Google Scholar]
  • 30.Rhodin JAG. Correlation of ultrastructural organization: and function in normal and experimentally changed proximal convoluted tubule cells of the mouse kidney: an electron microscopic study. Stockholm: Dept. of Anatomy, Karolinska Institutet; 1954. [Google Scholar]
  • 31.De Duve C, Baudhuin P. Peroxisomes (microbodies and related particles). Physiol Rev. 1966. Apr;46(2):323–57. doi: 10.1152/physrev.1966.46.2.323 [DOI] [PubMed] [Google Scholar]
  • 32.De Duve C. The peroxisome: a new cytoplasmic organelle. Proc R Soc London Ser B, Biol Sci. 1969. Apr;173(1030):71–83. 10.1098/rspb.1969.0039 [DOI] [PubMed] [Google Scholar]
  • 33.Sahara S, Yamashima T. Calpain-mediated Hsp70.1 cleavage in hippocampal CA1 neuronal death. Biochem Biophys Res Commun. 2010. Mar;393(4):806–11. doi: 10.1016/j.bbrc.2010.02.087 [DOI] [PubMed] [Google Scholar]
  • 34.Schaur RJ, Siems W, Bresgen N, Eckl PM. 4-Hydroxy-nonenal-A bioactive lipid peroxidation product. Biomolecules. 2015. Sep;5(4):2247–337. doi: 10.3390/biom5042247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Brereton MF, Vergari E, Zhang Q, Clark A. Alpha-, delta- and PP-cells: Are they the architectural cornerstones of islet structure and co-ordination? J Histochem Cytochem Off J Histochem Soc. 2015. Aug;63(8):575–91. 10.1369/0022155415583535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Saitoh S, Ohno N, Saitoh Y, Terada N, Shimo S, Aida K, et al. Improved serial sectioning techniques for correlative light-electron microscopy mapping of human langerhans islets. Acta Histochem Cytochem. 2018. Feb;51:9–20. doi: 10.1267/ahc.17020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Cnop M, Welsh N, Jonas J-C, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005. Dec;54 Suppl 2:S97–107. doi: 10.2337/diabetes.54.suppl_2.s97 [DOI] [PubMed] [Google Scholar]
  • 38.Marchetti P, Dotta F, Lauro D, Purrello F. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept. 2008. Feb;146(1–3):4–11. doi: 10.1016/j.regpep.2007.08.017 [DOI] [PubMed] [Google Scholar]
  • 39.Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest. 1994. Feb;93(2):870–6. doi: 10.1172/JCI117042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002. Feb;143(2):339–42. doi: 10.1210/endo.143.2.8623 [DOI] [PubMed] [Google Scholar]
  • 41.Weir GC. Glucolipotoxicity, β-Cells, and diabetes: The emperor has no clothes. Diabetes. 2020. Mar;69(3):273–8. doi: 10.2337/db19-0138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003. Mar;422(6928):173–6. doi: 10.1038/nature01478 [DOI] [PubMed] [Google Scholar]
  • 43.Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003. Mar;278(13):11303–11. doi: 10.1074/jbc.M211495200 [DOI] [PubMed] [Google Scholar]
  • 44.Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005. Apr;1(4):245–58. doi: 10.1016/j.cmet.2005.03.007 [DOI] [PubMed] [Google Scholar]
  • 45.Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes. 2009. May;58(5):1035–6. doi: 10.2337/db09-0215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab. 2013. Aug;24(8):398–407. doi: 10.1016/j.tem.2013.03.003 [DOI] [PubMed] [Google Scholar]
  • 47.Gautam J, Banskota S, Shah S, Jee J-G, Kwon E, Wang Y, et al. 4-Hydroxynonenal-induced GPR109A (HCA(2) receptor) activation elicits bipolar responses, G(αi) -mediated anti-inflammatory effects and G(βγ) -mediated cell death. Br J Pharmacol. 2018. Jul;175(13):2581–98. doi: 10.1111/bph.14174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Kunau WH, Dommes V, Schulz H. beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Prog Lipid Res. 1995. Dec;34(4):267–342. doi: 10.1016/0163-7827(95)00011-9 [DOI] [PubMed] [Google Scholar]
  • 49.Poirier Y, Antonenkov VD, Glumoff T, Hiltunen JK. Peroxisomal beta-oxidation—a metabolic pathway with multiple functions. Biochim Biophys Acta. 2006. Dec;1763(12):1413–26. doi: 10.1016/j.bbamcr.2006.08.034 [DOI] [PubMed] [Google Scholar]
  • 50.Fransen M, Nordgren M, Wang B, Apanasets O, Van Veldhoven PP. Aging, age-related diseases and peroxisomes. Subcell Biochem. 2013. Jun;69:45–65. doi: 10.1007/978-94-007-6889-5_3 [DOI] [PubMed] [Google Scholar]
  • 51.Islinger M, Grille S, Fahimi HD, Schrader M. The peroxisome: an update on mysteries. Histochem Cell Biol. 2012. May;137(5):547–74. doi: 10.1007/s00418-012-0941-4 [DOI] [PubMed] [Google Scholar]
  • 52.Fransen M. Peroxisome dynamics: Molecular players, mechanisms, and (dys)functions. ISRN Cell Biol. 2012;2012:714192. 10.5402/2012/714192 [DOI] [Google Scholar]
  • 53.Yokota S, Dariush Fahimi H. Degradation of excess peroxisomes in mammalian liver cells by autophagy and other mechanisms. Histochem Cell Biol. 2009. Apr;131(4):455–8. doi: 10.1007/s00418-009-0564-6 [DOI] [PubMed] [Google Scholar]
  • 54.Till A, Lakhani R, Burnett SF, Subramani S. Pexophagy: the selective degradation of peroxisomes. Int J Cell Biol. 2012;2012: 512721. doi: 10.1155/2012/512721 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Yokota S, Oda T, Fahimi HD. The role of 15-lipoxygenase in disruption of the peroxisomal membrane and in programmed degradation of peroxisomes in normal rat liver. J Histochem Cytochem Off J Histochem Soc. 2001. May;49(5):613–22. doi: 10.1177/002215540104900508 [DOI] [PubMed] [Google Scholar]
  • 56.Mayer A, Siegel NR, Schwartz AL, Ciechanover A. Degradation of proteins with acetylated amino termini by the ubiquitin system. Science. 1989. Jun;244(4911):1480–3. doi: 10.1126/science.2544030 [DOI] [PubMed] [Google Scholar]
  • 57.Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996. Jul;65:801–47. doi: 10.1146/annurev.bi.65.070196.004101 [DOI] [PubMed] [Google Scholar]
  • 58.van Leyen K, Duvoisin RM, Engelhardt H, Wiedmann M. A function for lipoxygenase in programmed organelle degradation. Nature. 1998. Sep;395(6700):392–5. doi: 10.1038/26500 [DOI] [PubMed] [Google Scholar]
  • 59.Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999. Aug;274(34):23679–82. doi: 10.1074/jbc.274.34.23679 [DOI] [PubMed] [Google Scholar]
  • 60.Xu J, Zhang Y, Xiao Y, Ma S, Liu Q, Dang S, et al. Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease. Cell Death Dis. 2013. Apr;4(4):e569. doi: 10.1038/cddis.2013.86 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Aleynik SI, Leo MA, Aleynik MK, Lieber CS. Alcohol-induced pancreatic oxidative stress: Protection by phospholipid repletion. Free Radic Biol Med. 1999. Mar;26(5–6):609–19. doi: 10.1016/s0891-5849(98)00246-9 [DOI] [PubMed] [Google Scholar]
  • 62.Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol Aging. 1997. Sep;18(5):457–61. doi: 10.1016/s0197-4580(97)00108-5 [DOI] [PubMed] [Google Scholar]
  • 63.Bruce-Keller AJ, Li YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, et al. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J Neuropathol Exp Neurol. 1998. Mar;57(3):257–67. doi: 10.1097/00005072-199803000-00007 [DOI] [PubMed] [Google Scholar]
  • 64.Leonarduzzi G, Chiarpotto E, Biasi F, Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol Nutr Food Res. 2005. Nov;49(11):1044–9. doi: 10.1002/mnfr.200500090 [DOI] [PubMed] [Google Scholar]
  • 65.Tang S-C, Arumugam T V, Cutler RG, Jo D-G, Magnus T, Chan SL, et al. Neuroprotective actions of a histidine analogue in models of ischemic stroke. J Neurochem. 2007. May;101(3):729–36. doi: 10.1111/j.1471-4159.2006.04412.x [DOI] [PubMed] [Google Scholar]
  • 66.Morquette B, Shi Q, Lavigne P, Ranger P, Fernandes JC, Benderdour M. Production of lipid peroxidation products in osteoarthritic tissues: new evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis Rheum. 2006. Jan;54(1):271–81. doi: 10.1002/art.21559 [DOI] [PubMed] [Google Scholar]
  • 67.Johnson JB, Summer W, Cutler RG, Martin B, Hyun D-H, Dixit VD, et al. Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med. 2007. Mar;42(5):665–74. doi: 10.1016/j.freeradbiomed.2006.12.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Kruman II, Mattson MP. Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis. J Neurochem. 1999. Feb;72(2):529–40. doi: 10.1046/j.1471-4159.1999.0720529.x [DOI] [PubMed] [Google Scholar]
  • 69.Yamashima T. Reconsider Alzheimer’s disease by the ‘calpain-cathepsin hypothesis’—a perspective review. Prog Neurobiol. 2013. Jun;105:1–23. doi: 10.1016/j.pneurobio.2013.02.004 [DOI] [PubMed] [Google Scholar]
  • 70.Yamashima T. Can “calpain-cathepsin hypothesis” explain Alzheimer neuronal death? Ageing Res Rev. 2016. Dec;32:169–79. doi: 10.1016/j.arr.2016.05.008 [DOI] [PubMed] [Google Scholar]
  • 71.Balogi Z, Multhoff G, Jensen TK, Lloyd-Evans E, Yamashima T, Jäättelä M, et al. Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. Prog Lipid Res. 2019. Apr;74:18–30. doi: 10.1016/j.plipres.2019.01.004 [DOI] [PubMed] [Google Scholar]
  • 72.Lou B. Boger M, Bennewitz K, Sticht C, Kopf S, Morgenstern J, et al. Elevated 4-hydroxynonenal induces hyperglycaemia via Aldh3a1 loss in zebrafish and associates with diabetes progression in humans. Redox Biol. 2020. Oct;37:101723. doi: 10.1016/j.redox.2020.101723 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

David Chau

8 Sep 2021

PONE-D-20-37303

Hydroxynonenal causes Langerhans cell degeneration in the pancreas of Japanese macaque monkeys

PLOS ONE

Dear Dr. Yamashima,

Thank you for submitting your manuscript to PLOS ONE.  Thank you for your patient whilst there has been a change in handling editor, and a preference from the editorial office to source reviewers with experience on using  monkeys as the model.

After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 5 days. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

David Chau

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ"

4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

5. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The rational behind the experiment was clear and straight forward. The manuscript is almost well written.

While many different sources are used to set up the study in the introduction, little previous evidence is

stated. The introduction is thus short and poorly sets up the rationale for the study. More attention to how

this study fits into previous work in oxidative and inflammation should be added to improve this section.

Please refer to doi: 10.3390/antiox9090781, 10.3390/antiox9100992

Reviewer #2: The authors investigated about the role of hydroxynonenal in both the carbonylation of Hsp70.1 and the activation of µ-calpain using Japanese macaque monkeys.

The rational behind the study was clear and straight forward. The manuscript is clearly written, its original and of interest in its field. However, the authors should better emphasize the conclusions.

I recommend that the paper be accepted with minor revision.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Nov 8;16(11):e0245702. doi: 10.1371/journal.pone.0245702.r002

Author response to Decision Letter 0


15 Sep 2021

PONE-D-20-37303

Hydroxynonenal causes Langerhans cell degeneration in the pancreas of Japanese macaque monkeys

PlosONE

Editorial Board

Dear Sirs,

Sept 11, 2021

This is to acknowledge for sending us two reviewer’s comments about the above paper. Their comments were extremely helpful for revising the manuscript.

As suggested by two reviewers, we have revised as followings.

---------------------------------------------------------------------------------------------------------Reviewer 1: The rational behind the experiment was clear and straight forward. The manuscript is almost well written. While many different sources are used to set up the study in the introduction, little previous evidence is stated. The introduction is thus short and poorly sets up the rationale for the study. More attention to how this study fits into previous work in oxidative and inflammation should be added to improve this section.

# The highlights portion shows sentences added or revised in the INTRODUCTION. We have revised so as to strengthen the rational studying implication of hydroxynonenal for the development of Langerhans cell degeneration in type 2 diabetes.

The pathogenesis of β-cell dysfunction leading to insulin resistance and impaired insulin secretion seen in type 2 diabetes is incompletely understood. Previous animal and in vitro studies demonstrated that chronic levels of oxidative stress are among the earliest abnormalities in the natural history of type 2 diabetes, although the evidence is insufficient [6]. On the other hand, the evidence for inflammation in the etiology of type 2 diabetes is broad, however, the underlying mechanism is also not well understood. Increased oxidative stress and inflammation, combined together, may lead to the pancreatic β-cell failure [1,2,3,4,5]. Elevated levels of inflammatory markers, pro-oxidants and various markers of oxidative tissue damage were found in the diabetic patients, which indicates their involvement in the occurrence of insulin resistance and impaired insulin secretion. Peroxidation of polyunsaturated fatty acids is intensified in cells subjected to oxidative stress and inflammation, and it results in the generation of various bioactive compounds [6,7,8,9,10]. Reactive aldehyde, especially hydroxynonenal, is considered as the representative cytotoxic product of lipid peroxidation causing long-lasting biological consequences, in particular, by covalent modification of macromolecules. Hydroxynonenal is a major aldehyde which was produced during the OH•-mediated peroxidation of ω-6 polyunsaturated fatty acids. In 2009, Oikawa et al. (2009) [16] found by the proteomic analysis that Hsp70.1 can be a target of oxidation (carbonylation) by hydroxynonenal. Subsequently, Sahara and Yamashima (2010) [33] demonstrated by the in-vitro experiment that Hsp70.1 being carbonylated by hydroxynonenal is prone to activated μ-calpain-mediated cleavage. Calpain-mediated cleavage of carbonylated Hsp70.1 leads to the lysosomal membrane rupture/permeabilization with the resultant release of cathepsins and cell death.

It is well-known that insulin resistance and impaired insulin signalling may be a contributory factor to the progression of type 2 diabetes. Although reduced release of insulin from β-cells is fundamental for both, the molecular mechanism of the Langerhans cell dysfunction caused by chronic inflammation and oxidative stress remains grossly unknown. Much progress has been made in identifying the molecular basis of lipotoxicity in the experimental systems, however whether or not this phenomenon actually plays an important role for the Langerhans cell degeneration remains debated especially in the primates [10]. To overcome this controversy, the authors thought that the experimental paradigm using non-human primates is indispensable. In the preliminary study, we confirmed that the intravenous injections of the synthetic hydroxynonenal induced cell death of diverse brain neurons and hepatocytes of the Japanese macaque monkeys [18]. To elucidate the etiology of the Langerhans cell degeneration/death causing impaired insulin secretion, we made an appropriate monkey model for an increased blood concentration of hydroxynonenal to analyse its toxic effects upon the Langerhans islet. We focused on the pancreas of monkeys to elucidate the molecular cascade processing in the primate organ. The pancreas of monkeys is large enough to supply sufficient amount of tissues necessary for the simultaneous analyses of immunofluorescence histochemistry, light and electron microscopy, and Western blotting in the given animal. Here, we report that hydroxynonenal can induce lysosomal membrane rupture/permeabilization by activated calpain-mediated cleavage of the carbonylated Hsp70.1 for the occurrence of Langerhans cell degeneration/death.

In addition, Ref 6 was changed, and Ref 72 was added.

Reviewer 2: The authors investigated about the role of hydroxynonenal in both the carbonylation of Hsp70.1 and the activation of µ-calpain using Japanese macaque monkeys. The rational behind the study was clear and straight forward. The manuscript is clearly written, its original and of interest in its field. However, the authors should better emphasize the conclusions.

# The CONCLUSION was completely revised to emphasize implication of ‘hydroxynonenal’ for the development of type 2 diabetes.

Conclusions

During the last four decades, hydroxynonenal, a major α,β-unsaturated aldehyde product of ω-6 fatty acid oxidation, has been shown to be involved in a great number of pathologies such as metabolic diseases, neurodegenerative diseases, and cancers. The present study indicated that a major pathophysiological mechanism behind the development of Langerhans cell degeneration/death is oxidative stress mediated by hydroxynonenal. By carbonylating a lysosomal stabilizer, Hsp70.1, hydroxynonenal contributes to the occurrence of lysosomal membrane rupture/permeabilization in the Langerhans cells, which lead to their degeneration/death. Calpain activation by hydroxynonenal may contribute to cleavage of the oxidized (carbonylated) Hsp70.1. In case of the above diseases, chronic ischemia and/or inflammation may also facilitate calpain activation. The low defense against exogenous hydroxynonenal and peroxisomally-generated hydrogen peroxide, was presumably overwhelmed in the Langerhans islets. The authors speculate from the present monkey data that ‘hydroxynonenal’ might be a real culprit behind type 2 diabetes in humans. Future studies focusing on the earlier phase of hydroxynonenal toxification in vivo, are needed to elucidate the molecular mechanism of the Langerhans cell pathology for the development of type 2 diabetes.

# The end of DISCUSSION was also modified a little bit.

Concerning the molecular mechanism of ischemic neuronal death, Yamashima et al. formulated the ‘calpain-cathepsin hypothesis’ in 1998 [14]. Thereafter, concerning the mechanism of Alzheimer’s neuronal death, they suggested that Hsp70.1 with dual functions of molecular chaperone and lysosomal stabilizer becomes vulnerable to the cleavage by activated μ-calpain, which is facilitated after Hsp70.1 oxidation (carbonylation) by hydroxynonenal [33,69,70,71]. Elevated hydroxynonenal was recently reported to be responsible for hyperglycemia and correlated with HbA1c in both experimental animals and humans [72], although the precise role of hydroxynonenal in type 2 diabetes is not well understood until now. Due to the hydroxynonenal-induced carbonylation with the subsequent calpain-mediated cleavage of carbonylated Hsp70.1, functional Hsp70.1 decreases steadily. This results in both accumulation of autophagosomes and permeabilization/rupture of the lysosomal membrane (Fig. 8). It is likely that autophagy deficiency and lysosomal failure are occurring simultaneously. By inducing Hsp70.1 disorder, hydroxynonenal conceivably plays sinister roles in the occurrence of degeneration/death of Langerhans cells, leading to type 2 diabetes.

Applying the data of the present monkey experimental paradigm to consider human diseases, both the dietary ω-6 fatty acid- (exogenous; from cooking oils, deep-fried foods, etc.) and the biomembrane phospholipid- (intrinsic; from the circumstance containing electromagnetic wave, air pollution, etc.) peroxidation product hydroxynonenal, when combined, conceivably plays crucial roles for the lysosomal cell death not only in the pancreas but also in the brain. The authors speculate that not only type 2 diabetes but also Alzheimer’s disease might occur in response to the exogenous and intrinsic hydroxynonenal by the long-standing lysosomal cell death in the corresponding organ [11].

# According to the helpful suggestion, Reference [72] was added to support an implication of hydroxynonenal to type 2 diabetes by the previous report.

----------------------------------------------------------------------------------------------------------

The authors do hope these corrections are satisfactory for the final acceptance.

With warmest regards,

Tetsumori YAMASHIMA, MD, PhD

Kanazawa University Graduate School of Medicine

Japan

Attachment

Submitted filename: Response to Reviewers.pdf

Decision Letter 1

David Chau

25 Oct 2021

Hydroxynonenal causes Langerhans cell degeneration in the pancreas of Japanese macaque monkeys

PONE-D-20-37303R1

Dear Dr. Yamashima,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

David Chau

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

David Chau

29 Oct 2021

PONE-D-20-37303R1

Hydroxynonenal causes Langerhans cell degeneration in the pancreas of Japanese macaque monkeys

Dear Dr. Yamashima:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. David Chau

Academic Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES